Human bone marrow contains a distinct cell population that expresses bone proteins and responds to transforming growth factor p1 (TGF-,B), but not to hematopoietic growth factors (Long, M. W., J. L. Williams, and K. G. Mann. 1990 . J. Clin. Invest. 86:1387-1395. We now report the isolation, characterization, and growth factor responsiveness of these precursors to human osteoblasts and the identification of a human osteoprogenitor cell. Immunological separation of human bone marrow nonadherent low-density (NALD) cells results in a marked enrichment of cells that express osteocalcin, osteonectin, and bone alkaline phosphatase. Flow cytometric analyses show that distinct cell subpopulations exist among these isolated cells. The majority of the bone antigen-positive cells are approximately the size of a lymphocyte, whereas other, less frequent antibody-separated subpopulations consist of osteoblast-like cells and osteoprogenitor cells. In serum-free cultures, TGF-.8 stimulates the small, antigen-positive cells to become osteoblastlike, as these cells both increase in size, and express increased levels of osteocalcin and alkaline phosphatase. Antibody-separated cells also contain a separate population of clonal progenitor cells that form colonies of osteoblast-like cells when cultured in serum-free, semi-solid media. Two types of human osteoprogenitor cells are observed: a colonyforming cell (CFC) that generates several hundred bone antigen-positive cells, and a more mature cluster-forming cell that has a lesser proliferative potential and thus generates clusters of 20-50 antigen-positive cells. Osteopoietic colony-forming cells and cluster-forming cells have an obligate but differential requirement for osteogenic growth factors. The CFCs respond to TGF-,B, basic fibroblast growth factor (bFGF), bone morphogenic protein-2 (BMP-2), and 1, 25-dihydroxy vitamin D3 (1,25-OH D3). In contrast to the colony-forming cells, cluster-forming cells are regulated predominately by 1,25-OH D3 and TGF-fi, but fail to respond to bFGF. We conclude that human bone marrow Clin. Invest. 1995. 95:881-887.)
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Introduction
Bone development results from the proliferation of mesenchymal cells, their differentiation into osteogenic progenitor cells, and the eventual calcification of cartilage and bone extracellular matrix (1) . During this developmental process, bone also forms a central marrow in which hematopoietic cell differentiation occurs. One of the unresolved areas concerning bone formation is the nature of the developmental lineage(s) leading to the formation of each bone cell type: the osteoblast and osteoclast. Previous studies suggest that osteoblasts arise in some unknown manner from local mesenchymal cells (2, 3) , whereas osteoclasts may be the progeny of macrophages/monocytes (2, (4) (5) (6) . However, exact information concerning the nature of the stem cell population(s) capable of both proliferating and differentiating into bone-forming osteoblasts is limited. We report the isolation and characterization of human bone precursor cells from nonadherent low-density (NALD)' bone marrow cell populations. Isolated bone precursor cells are of three types: osteoprogenitor cells, preosteoblast, and osteoblast-like cells. Each of these subpopulations shows a differential responsiveness to osteogenic stimuli.
Methods
Bone marrow cell preparation and cell culture. Human bone marrow aspirates were obtained from normal volunteers after informed consent. Bone marrow cells were subjected to adherent cell depletion and density separation techniques as described previously (7) . Briefly, NALD cells were prepared by first subjecting the cells to equilibrium-density centrifugation (Ficoll; Sigma Chemical Co., St. Louis, MO). The resultant mononuclear, low-density cells (i. e., those cells at the Ficoll interface of -1.077 g/cm3) next were subjected to two rounds of plastic adherence (to remove marrow stromal cells) (8) For flow cytometric analysis, cells were harvested immediately after immune adherence (as day 0 or input) and on day 7, either with a rubber policeman or by trypsinization using trypsin/EDTA (Gibco). The antigenic profiles of bone proteins are equivalent with either procedure (not shown), but scraping tends to reduce the total cell recovery. To quantify osteoprogenitor cells in immune-adherent cultures, adherent cells were cultured in situ in a fibrin-clot system. In these assays, immune-adherent cells (as above) are first checked microscopically to insure that no cell aggregates are present and then over-layered with fibrinogen-containing media which also contained the given -amounts'of the indicated osteogenic growth factors. A given growth factor was present for all 7 d of the culture period. Adherent cells are overlayered with McCoy's/ITS+ media containing plasminogen-free fibrinogen (2 mg/ml) (Hematologic Technologies, Burlington, VT). The fibrinogen is then treated with human thrombin (1 U/ml) to form a fibrin clot. The known capacity of osteoblasts to produce proteolytic enzymes and thus lyse the clot was overcome by using epsilon-amino caproic acid at a concentration of 5 mM and repletion with more fibrinogen, as needed. Additional fibrinogen is usually required on days 3 and 5. Immunocytochemistry for osteocalcin expression in osteoprogenitor cell colonies was performed as previously reported (9), except that diaminobezadine concentration was 3 mg/ml and the substrate incubation period was increased to 2 h. Immunocytochemistry controls consisted of an inappropriate antibody, secondary antibody only, and diaminobezadine only (to assess endogenous peroxidase activity). These controls were uniformly negative (data not shown).
Results and Discussion
Isolation and enrichment of bone protein-expressing cells. A number of noncollagenous proteins play a role in bone formation. We used monoclonal antibodies to two of these bone proteins, osteocalcin and osteonectin, both as phenotypic markers of bone cell development and as a mechanism of isolating bone 882 Long, Robinson, Ashcraft, and Mann protein-expressing cells in vitro. Osteonectin (also known as SPARC) is present in high concentration in bone of the axial skeleton and skull (13, 14) . Osteonectin binds to calcium, hydroxyapatite, and collagen and, thus, may regulate mineral deposition in bone matrix ( 15) . Another bone protein, osteocalcin (also known as bone gla-protein or BGP), is a vitamin Kdependent protein that is specific for bone and also binds calcium (15) (16) (17) (18) . We also used a monoclonal antibody to bone alkaline phosphatase (see Methods) as a phenotypic marker for bone cells. Our previous data demonstrated that marrow-derived osteoblast-like cells modify extracellular matrix in an osteogenic fashion (9) . Coupled with the present data on antigenic phenotyping and in vitro expansion (see below), we herein define marrow-derived preosteoblasts as small, proliferating cells (lymphocyte-sized) that express low amounts of bone protein antigens, whereas marrow-derived osteoblast-like cells are the larger, differentiated progeny of these cells which express high amounts of antigen and, with longer culture (see reference 9), generate osteoid-like matrix.
Monoclonal antibodies to osteocalcin and osteonectin (10, 11) were used to capture ("pan") bone protein-expressing NALD cells using conventional immune-adherence technology ( 19, 20) . Immune-adherence isolation produces a markedly enriched population of cells that are 40-60% bone protein antigen-positive. Subpopulations of these cells are further resolved using multiparameter fluorescence-activated flow cytometry (Fig. 1) . The first subpopulation comprises the majority of the cells and is distinguished as a group of bone antigen-positive preosteoblasts approximately the size of a lymphocyte. A second population of antigen-positive osteoblast-like cells is larger than the upper 95% limit of unfractionated NALD cell populations and comprises -2-4% of the immune-adherent cell population (Fig. 1, top) . Both antigen-positive small and large cells express osteocalcin, bone alkaline phosphatase (Fig. 1, top) , and osteonectin (not shown). The exact developmental level at which bone precursor cells express these antigens is unknown.
However, preliminary two-color fluorescence cytometry studies indicate that the majority ( 2 70%) of the immune-isolated cells coexpress both osteonectin and BGP, whereas the remainder express either osteocalcin or osteonectin.
In vitro expansion and differentiation of bone marrowderived bone cells. Immune-isolated cells were cultivated under serum-free conditions in the presence of TGF-31. Multi-parameter flow cytometry indicates that TGF-/3 treatment causes the small cells to differentiate into large, bone protein antigen-positive cells (Fig. 1, bottom) tive cell numbers during the loss of nonspecific (i. e., antigennegative) cell populations. Confirming the former, examination of the total cellularity per culture shows an approximate threeto fourfold in vitro expansion in the total number of osteoblastlike cells over a 7-d period (Fig. 2 B) , while the antigennegative cell number remains unchanged or diminished (not shown). This is true for both BGP-expressing cells as well as alkaline phosphatase-positive cells. These data do not, however, exclude the formal possibility that the small preosteoblastlike cells die off in culture while the larger osteoblast-like cells proliferate to become the predominant cell population. However, we consider this possibility unlikely as osteoblasts have low, if any, proliferative capacity. We conclude that it is more likely that immune selection of bone protein antigen-positive cells yields a TGF-f3-responsive population of small preosteoblasts that is capable of differentiating into osteoblast-like cells. In either case, the result is an in vitro expansion of osteoblastlike cells.
In vitro development of human osteoprogenitor cells. We hypothesized that among the immune-isolated bone precursor cells there might exist a true bone progenitor cell, i. e., precursor cells capable of undergoing clonal expansion into differentiated progeny. The clonal nature and in vitro characteristics of progenitor cells in other systems are well described: progenitor cell growth and development requires the presence of at least one mitogenic growth factor, and cell growth in an inert, semi-solid 3-dimensional matrix which results in the clonal formation of cell colonies by restricting the outgrowth of differentiated progeny (reference 21 and references therein). To detect osteoprogenitor cells, immune-isolated NALD cells were over-layered with chemically defined, serum-free media containing fibrinogen, which is subsequently treated with thrombin to form a fibrin clot. Cells were cultured for 7 d under serum-free conditions in the presence of TGF-P (or other growth factors, see below). Subsequently, the fibrin clot was dried to a film, and the cultures were subjected to immunocytochemical analysis.
Two types of progenitor cell-derived colonies are observed after 7 d. One colony phenotype consists of small clusters of cells containing 20-50 osteocalcin-positive cells (Fig. 3 A) . By convention, this type of progenitor cell is referred to as a cluster-forming cell (21, 22) and represents a progenitor cell with limited proliferative potential. The second type of osteogenic cell growth consists of colonies containing several hundred intensely osteocalcin-positive cells (Fig. 3 B) . This latter type of colony-forming cell (CFC) thus represents an osteoprogenitor cell with an increased proliferative potential. Under appropriate growth factor conditions (see below), this type of progenitor cell is present at 20-50 CFC per IO' total immune-adherent cells. Both colony types are observed in the same cultures. The relationship between the number of adherent cells cultured and number of colonies observed is linear, thus demonstrating that colony formation is clonal (i. e., one progenitor cell gives rise to one colony) (Fig. 4) . These two types of progenitor cell growth are consistent with previous observations in other systems in which CFC are felt to be more primitive than clusterforming cells (21, 22) . Therefore, the cluster-forming cell represents a later (more mature) stage of bone cell development than the CFC (i. e., the CFC colony is developmentally antecedent to the CFC cluster).
Both cluster-forming and colony-forming osteoprogenitor cells show an obligate requirement for growth factors and a differential responsiveness to bone-regulatory cytokines (Fig.  5 ). Both progenitor cell types fail to develop in the absence of osteogenic growth factors (media controls, Fig. 5 ), whereas the addition of recombinant human growth factors known to regulate osteoblasts (23) (24) (25) (26) (27) stimulates both cluster and colony formation. The colony-forming progenitor cells respond equally well to TGF-,3 and human recombinant basic fibroblast growth factor (bFGF), generating -40-60 colonies per IO' cells (Fig.   5 A) . Likewise, 1, 25-dihydroxy vitamin D3 (1,25-OH D3) and bone morphogenic protein-2 (BMP-2) both stimulate CFC but to a lesser degree than that seen with TGF-,3 or bFGF. In contrast to the CFC, progenitor cells which form clusters respond well to 1,25-OH D3, whereas they respond less well to BMP-2 and TGF-3 (Fig. 5 B) . Of interest, bFGF fails to drive the formation of osteogenic clusters, suggesting a role for this growth factor only in the early phases in bone progenitor cell development.
One of the difficulties in dissecting cell lineages is the need to precisely define developmental stages. We combined immune-isolation, flow cytometric multiparameter analysis, and functional assays (colony formation and growth factor responsiveness) to characterize human marrow-derived bone precursor cells. Thus, the proliferative component of this lineage consists of two types of osteoprogenitor cells (the colony-and clusterforming cells) as well as the preosteoblasts, each distinguished by their cell size, growth factor responsiveness, and proliferative potential. The remaining isolated bone cells are the osteoblastlike cells that express increased amounts of bone proteins in response to TGF-f31, have a low proliferative potential (if any), and elaborate and mineralize a collagen and noncollagenous bone protein-containing extracellular matrix (reference 9 and data therein). As a matter of definition, a progenitor cell is a proliferating precursor cell that is restricted to a given lineage (in this case, osteoblastic) and is capable of generating clonal, differentiated progeny. During its development, this cell progressively looses its proliferative capacity, differentiating into an end-stage cell (e. g., an osteoblast). The in vitro correlate of this process is the formation of a colony, or cluster, respective to the progenitor cell's proliferative potential. As stated, we observe one colony phenotype which consists of small clusters of cells containing osteocalcin-positive cells, and a second colony type of several hundred intensely osteocalcin-positive cells. This latter type of CFC thus represents an osteoprogenitor cell with an increased proliferative potential. Therefore, the cluster-forming cell represents a later (more mature) stage of bone cell development than the CFC (i. e., the CFC colony is developmentally antecedent to the CFC cluster). The literature on the growth characteristics of these two progenitor types extends over 30 yr and is too large to review here (for review see reference 28 and references therein). However, it is a logical and reasonable interpretation of the composite data that clusterforming cells are the progeny of CFC and that these exist as distinct cell subpopulations. While Figure 3 . Human bone marrow-derived osteoprogenitor cell colonies. Immune-adherent bone antigen-positive cells were cultured in serum-free tissue culture medium (9) containing plasminogen-free fibrinogen, which was treated with thrombin (35) to form a fibrin clot. After 7 d of culture, the fibrin clots were dried to a film and subjected to immunocytochemical analysis using monoclonal antibodies to human BGP (osteocalcin) as described elsewhere (10) . bone marrow-derived bone precursor cells were not hematogenous in origin, as these cells did not express the pan-hematopoietic cell surface antigen CD34 and failed to respond to hematopoietic growth factors (9) . Moreover, unlike the murine system, human bone marrow-initiated bone cell cultures cannot be derived from bone marrow stromal cells (9 The relationship between bone marrow-derived human osteoprogenitor cells and past reports on bone formation derived from the colony-forming unit fibroblast (CFU-f) (29) (30) (31) (12, 34) . Pragmatically, this requires that investigations into the control of a given cellular lineage use purified progenitor cell populations, serum-free culture conditions, and purified (e. g., recombinant) growth factors. We have shown that human bone marrow-derived bone progenitor cells can be purified by immunological selection for bone protein antigens, cultured in chemically defined, serum-free conditions, and stimulated with purified, bone-active growth factors. The study of these cells will be important to the understanding of bone cell biology in health and disease.
